SGMO Sangamo Therapeutics Inc.

7.42
+0.17  (+2%)
Previous Close 7.26
Open 7.3
Price To Book 2.06
Market Cap 860,836,814
Shares 115,937,618
Volume 111,379
Short Ratio
Av. Daily Volume 1,779,407
Stock charts supplied by TradingView

NewsSee all news

  1. Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on

  2. Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment

    - Pfizer advancing SB-525 for Hemophilia A to a Phase 3 registrational study in 2020 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene

  3. Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day

    IND transfer to Pfizer for SB-525 hemophilia A gene therapy is substantially completed; Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 At R&D Day, Sangamo is detailing global

  4. Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia

    First three patients experienced prompt hematopoietic reconstitution, and no clonal hematopoiesis Early first-in-human data provide insights into relationship between product specific characteristics, including cell

  5. Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

    - The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively - All five patients in the 3e13

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in 2020.
SB-525
Hemophilia A
Phase 1/2 further data due late-2020.
ST-400
beta-thalassemia
Next trial to be initiated in 2020.
SB-318
MPS Type 1
Phase 1/2 data to accumulate throughout 2019.
SB-FIX
Hemophilia B
Phase 1/2 ongoing with data to accumulate throughout 2019.
SB-913 - CHAMPIONS
MPS Type 2
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B
Phase 1/2 to commence enrolment by end of 2019.
ST-920
Fabry disease
Phase 1/2 trial to be initiated in 2020.
TX200
Kidney transplantation

Latest News

  1. Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on

  2. Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment

    - Pfizer advancing SB-525 for Hemophilia A to a Phase 3 registrational study in 2020 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene

  3. Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day

    IND transfer to Pfizer for SB-525 hemophilia A gene therapy is substantially completed; Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 At R&D Day, Sangamo is detailing global

  4. Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia

    First three patients experienced prompt hematopoietic reconstitution, and no clonal hematopoiesis Early first-in-human data provide insights into relationship between product specific characteristics, including cell

  5. Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

    - The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively - All five patients in the 3e13

  6. Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives and

  7. Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the

  8. Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation

    The STEADFAST clinical study of TX200 is the first-in-human trial to evaluate a CAR-Treg cell therapy Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the United Kingdom's (UK)

  9. Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London,

  10. Sangamo Therapeutics Announces New Scientific Advisory Board

    Members include distinguished international experts across a diverse range of scientific and therapeutic areas Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that is has

  11. Sangamo Therapeutics Reports Third Quarter 2019 Financial Results

    Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business

  12. Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster

  13. Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019. Mr. Lee oversees

  14. Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November

  15. Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all

  16. Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that members of the management team will present at the following investor and industry conferences in October: Cell & Gene

  17. Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that management will present at the following investor conferences in September: Wells Fargo 2019 Healthcare